Submit a Late Breaking Clinical Science Abstract
The ISHLT2019 Abstract Submission Site is now closed.
The Late-Breaking Clinical Science
abstract category is intended to facilitate the presentation of high-impact multi-center studies or particularly provocative single-center investigations. In general, such studies would include prospective, randomized trials that seek to investigate new approaches to the diagnosis and/or treatment of cardiothoracic diseases relevant to the field and that have the potential to alter our contemporary treatment paradigm.
To assure that truly "late-breaking" information is included in the meeting, authors may submit “place-holder” abstracts describing trials and studies that are not yet completed as of October 23, 2018
have results and conclusions available by March 6, 2019
. The abstract submitted by the October 23, 2018, deadline will serve as a placeholder for the final abstract.
Studies which have results and conclusions by October 23, 2018 will not be considered late-breaking and should be submitted in the Abstract area.
Abstracts presenting an interim analysis of clinical trial data will not be accepted unless the intention to conduct an interim analysis was predetermined in the trial protocol before the study commenced.
If you wish to have a revised version of your abstract with interim study findings published in the abstract supplement to the Journal of Heart and Lung Transplantation
, ISHLT MUST receive a revised version of the abstract reflecting the interim study findings NO LATER THAN January 16, 2019
: The Presenting Author of an accepted Late-Breaking Clinical Science abstract must submit the final analysis of the study results and conclusions to Susie Newton (firstname.lastname@example.org
) by March 6, 2019. Failure to submit this data by the deadline may result in the withdrawal of the presentation from the program. The final analysis will be seen only by a closed ISHLT scientific panel to ensure complete confidentiality of the results prior to presentation. ISHLT reserves the final decision regarding scheduling of Late-Breaking Clinical Science presentations.
An invitation to give a presentation based on a submitted abstract cannot be withdrawn simply because the results do not conform to expectations.